ES2548575T3 - Procedimiento para la síntesis de 4,5,6,7-tetracloro-3',6'-dihidroxi-2',4',5',7'-tetrayodo-3H-espiro[isobenzofuran-1,9'-xanten]-3-ona (Rosa de Bengala) y xantenos relacionados - Google Patents
Procedimiento para la síntesis de 4,5,6,7-tetracloro-3',6'-dihidroxi-2',4',5',7'-tetrayodo-3H-espiro[isobenzofuran-1,9'-xanten]-3-ona (Rosa de Bengala) y xantenos relacionados Download PDFInfo
- Publication number
- ES2548575T3 ES2548575T3 ES10817918.5T ES10817918T ES2548575T3 ES 2548575 T3 ES2548575 T3 ES 2548575T3 ES 10817918 T ES10817918 T ES 10817918T ES 2548575 T3 ES2548575 T3 ES 2548575T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- compound
- independently
- impurities
- xanten
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Abstract
Un procedimiento para la producción de un compuesto de Fórmula 4a: **Fórmula** en donde R1 es independientemente Cl o Br; R11 y R12 son independientemente H, Na, K, Li, o un contraión capaz de formar una sal farmacéuticamente aceptable, que comprende combinar un compuesto de Fórmula 3a, o un isómero del mismo en donde el compuesto quinoide de Fórmula 3a, o el isómero quinoide del mismo, están sustancialmente libres de impurezas de iones cloruro y de impurezas productoras de iones cloruro**Fórmula** en donde R1 es independientemente Cl o Br; R2, R3, R4 y R5 son H; cuyo método se lleva a cabo con al menos aproximadamente 4 equivalentes de yodo, en una solución sustancialmente libre de iones cloruro y sustancialmente libre de impurezas productoras de iones cloruro para formar el compuesto de Fórmula 4a, caracterizado porque no hay sustancialmente formación de derivados transhalogenados del compuesto de Fórmula 4b, en donde para las impurezas transhalogenadas del compuesto de Fórmula 4b, R1 es independientemente Cl o Br; al menos uno de R2, R3, R4 y R5 es Cl y el resto son I; R11 y R12 son independientemente H, Na, K, Li, o un contraión capaz de formar una sal farmacéuticamente aceptable; **Fórmula**
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24370109P | 2009-09-18 | 2009-09-18 | |
US243701P | 2009-09-18 | ||
PCT/US2010/049341 WO2011035161A1 (en) | 2009-09-18 | 2010-09-17 | Process for the synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5'7'-tetraiodo-3h-spiro[isobenzofuran-1,9'-xanthen]-3-one (rose bengal) and related xanthenes |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2548575T3 true ES2548575T3 (es) | 2015-10-19 |
Family
ID=43757167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10817918.5T Active ES2548575T3 (es) | 2009-09-18 | 2010-09-17 | Procedimiento para la síntesis de 4,5,6,7-tetracloro-3',6'-dihidroxi-2',4',5',7'-tetrayodo-3H-espiro[isobenzofuran-1,9'-xanten]-3-ona (Rosa de Bengala) y xantenos relacionados |
Country Status (10)
Country | Link |
---|---|
US (2) | US8530675B2 (es) |
EP (1) | EP2464225B8 (es) |
JP (1) | JP5671040B2 (es) |
KR (1) | KR101494055B1 (es) |
CN (1) | CN102548406B (es) |
CA (1) | CA2771988C (es) |
ES (1) | ES2548575T3 (es) |
HK (2) | HK1172501A1 (es) |
MX (1) | MX2012003063A (es) |
WO (1) | WO2011035161A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103476943A (zh) | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | 用于增强治疗癌症的局部和全身性免疫调节疗法的组合 |
US20150111301A1 (en) | 2013-10-22 | 2015-04-23 | The Government Of The United States As Represented By The Secretary Of The Air Force | Rose bengal for detection of oxidative decomposition of contaminants |
JP7015232B2 (ja) * | 2018-11-21 | 2022-02-02 | 東レ・ファインケミカル株式会社 | 高純度のフルオレセイン類化合物の製造方法 |
US11975106B2 (en) | 2020-03-26 | 2024-05-07 | Provectus Pharmatech, Inc. | Uses of halogenated xanthenes in oncology and virology |
US11938182B2 (en) | 2020-03-26 | 2024-03-26 | Provectus Pharmatech, Inc. | Halogenated xanthenes as vaccine adjuvants |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE108838C (es) | ||||
US1931049A (en) * | 1931-11-21 | 1933-10-17 | Nat Aniline & Chem Co Inc | Process of making dihydroxyfluoranes |
US1965842A (en) * | 1931-11-21 | 1934-07-10 | Nat Aniline & Chem Co Inc | Production of hydroxybenzenephthaleins |
US3829440A (en) * | 1972-12-21 | 1974-08-13 | Richardson Merrell Inc | Xanthene derivatives |
SU517222A1 (ru) | 1974-10-25 | 1977-06-25 | Институт Биофизики Министерства Здравохранения Ссср | Способ получени препарата бенгальска роза, меченного радиоизотопами йода |
SU792878A1 (ru) | 1978-08-29 | 1982-02-07 | Ленинградский институт ядерной физики им. Б.П.Константинова | Способ получени галогенированных производных флуоресцеина,меченных радиоизотопом йода |
DE3071373D1 (en) | 1980-10-27 | 1986-03-06 | Syva Co | Novel ether substituted fluorescein compounds as fluorescers and quenchers |
SU992516A1 (ru) | 1981-06-11 | 1983-01-30 | Ленинградский Институт Ядерной Физики Им.Б.П.Константинова | Способ получени галогенированных производных флуоресцеина,меченных радиоизотопом иода -123 |
ES8606451A1 (es) | 1985-10-28 | 1986-04-16 | Zoster Sa | Procedimiento para la obtencion de la eritrosina sodica |
IN168346B (es) | 1987-09-07 | 1991-03-16 | Council Scient Ind Res | |
US5637733A (en) * | 1995-09-27 | 1997-06-10 | Warner-Jenkinson Company, Inc. | Syntheses of fluorescein compounds with excess resorcinol as a solvent |
CA2235343A1 (en) * | 1995-10-23 | 1997-05-01 | Marizel Rouilly | Optical sensor system for the determination of ph values independently of ionic strength |
US6162931A (en) * | 1996-04-12 | 2000-12-19 | Molecular Probes, Inc. | Fluorinated xanthene derivatives |
US5945526A (en) * | 1996-05-03 | 1999-08-31 | Perkin-Elmer Corporation | Energy transfer dyes with enhanced fluorescence |
US6331286B1 (en) | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
US7648695B2 (en) * | 1998-08-06 | 2010-01-19 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
US6372907B1 (en) * | 1999-11-03 | 2002-04-16 | Apptera Corporation | Water-soluble rhodamine dye peptide conjugates |
US6448407B1 (en) | 2000-11-01 | 2002-09-10 | Pe Corporation (Ny) | Atropisomers of asymmetric xanthene fluorescent dyes and methods of DNA sequencing and fragment analysis |
AU2002256991A1 (en) | 2001-02-05 | 2002-08-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt | Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein |
US6800765B2 (en) * | 2001-08-02 | 2004-10-05 | Molecular Devices Corporation | Fluorescent pH indicators for intracellular assays |
CA2490961A1 (en) * | 2002-07-01 | 2004-01-08 | Guava Technologies, Inc. | Fluorescent dyes, energy transfer couples and methods |
FR2846331B1 (fr) * | 2002-10-29 | 2006-11-17 | Synth Innove Lab | Phtaleines de purete elevee et leur procede de preparation |
WO2004078851A1 (en) * | 2003-02-28 | 2004-09-16 | Polaroid Corporation | Novel dyes and use thereof in thermal imaging members and methods |
CA2570687C (en) * | 2004-06-10 | 2013-07-09 | Xantech Pharmaceuticals, Inc. | Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes and methods for positron emission imaging with radiolabeled halogenated xanthene diagnostic agents |
CN1331797C (zh) * | 2005-04-30 | 2007-08-15 | 南京师范大学 | 无氯无碱多功能复合混凝土矿渣掺合料及其生产方法 |
CA2657691A1 (en) * | 2006-06-19 | 2007-12-27 | Vanderbilt University | Methods and compositions for diagnostic and therapeutic targeting of cox-2 |
GB0613287D0 (en) | 2006-07-05 | 2006-08-16 | Ge Healthcare Ltd | Dye imaging agents |
ITMI20061713A1 (it) * | 2006-09-08 | 2008-03-09 | St Microelectronics Srl | Procedimento per la sintesi di derivati alogenati della fluoresceina utili nella produzione di dispositivi di memoria non volatile |
-
2010
- 2010-09-17 US US12/884,833 patent/US8530675B2/en active Active
- 2010-09-17 CA CA2771988A patent/CA2771988C/en active Active
- 2010-09-17 ES ES10817918.5T patent/ES2548575T3/es active Active
- 2010-09-17 MX MX2012003063A patent/MX2012003063A/es unknown
- 2010-09-17 EP EP10817918.5A patent/EP2464225B8/en active Active
- 2010-09-17 WO PCT/US2010/049341 patent/WO2011035161A1/en active Application Filing
- 2010-09-17 CN CN201080041506.7A patent/CN102548406B/zh active Active
- 2010-09-17 KR KR1020127009834A patent/KR101494055B1/ko active IP Right Grant
- 2010-09-17 JP JP2012529937A patent/JP5671040B2/ja active Active
-
2012
- 2012-09-17 HK HK12109116.6A patent/HK1172501A1/xx unknown
- 2012-12-20 HK HK12113215.8A patent/HK1172212A1/zh unknown
-
2013
- 2013-06-12 US US13/916,408 patent/US9422260B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HK1172501A1 (en) | 2013-04-26 |
US20130274322A1 (en) | 2013-10-17 |
CA2771988C (en) | 2016-07-05 |
KR20120091088A (ko) | 2012-08-17 |
EP2464225A4 (en) | 2013-03-27 |
KR101494055B1 (ko) | 2015-02-16 |
US9422260B2 (en) | 2016-08-23 |
MX2012003063A (es) | 2012-07-25 |
US8530675B2 (en) | 2013-09-10 |
US20110071217A1 (en) | 2011-03-24 |
WO2011035161A1 (en) | 2011-03-24 |
EP2464225B8 (en) | 2017-08-23 |
EP2464225A1 (en) | 2012-06-20 |
CN102548406A (zh) | 2012-07-04 |
JP5671040B2 (ja) | 2015-02-18 |
JP2013505261A (ja) | 2013-02-14 |
HK1172212A1 (zh) | 2013-04-19 |
CN102548406B (zh) | 2015-04-08 |
CA2771988A1 (en) | 2011-03-24 |
EP2464225B1 (en) | 2015-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2548575T3 (es) | Procedimiento para la síntesis de 4,5,6,7-tetracloro-3',6'-dihidroxi-2',4',5',7'-tetrayodo-3H-espiro[isobenzofuran-1,9'-xanten]-3-ona (Rosa de Bengala) y xantenos relacionados | |
ES2655911T3 (es) | Compuestos de tetraciclina sustituidos con C7-fluoro | |
ECSP066688A (es) | Polimorfo cristalino de una sal de bisulfato de underivados de azepinoindol como agentes farmaceuticos antagonista del receptor de trombina | |
ES2585330T3 (es) | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto inhibitorio en la producción de quinurenina | |
MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
MY165906A (en) | Phenothiazine diaminium salts and their use | |
UA122435C2 (uk) | Гетероциклічна сполука | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
IN2014MN02106A (es) | ||
CR20140301A (es) | Derivados de betulina | |
AR066130A1 (es) | Formas cristalinas de saxagliptina y procesos para preparar las mismas | |
TN2014000033A1 (fr) | Indazoles | |
CO6251288A2 (es) | Novedosas fenilpirrolidinas disustuidas como moduladores de la neurotransmision catecolaminergica cortical | |
MX2011009807A (es) | Compuestos. | |
MX2012001463A (es) | Proceso para la fabricacion de compuestos. | |
MA34965B1 (fr) | Procédé de production de dérivé de dihydrobenzofurane optiquement actif | |
EA201200763A1 (ru) | Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep | |
UY31367A1 (es) | Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica | |
CR20120269A (es) | Derivados de etinilo | |
ECSP099708A (es) | Nuevos métodos | |
ECSP14013296A (es) | Derivados de etinilo | |
MA33027B1 (fr) | Nouveau procede de synthese de l'ivabradine zet de ses sels d'addition a un acide pharmaceutiquement acceptable | |
CO7400864A2 (es) | Moduladores selectivos del receptor de andrógenos novedosos | |
AR077960A1 (es) | Derivados de benzamida n-sustituidos como inhibidores del transportador de glicina 1 (glyt-1) |